D E Furst

3.8k total citations
40 papers, 1.9k citations indexed

About

D E Furst is a scholar working on Rheumatology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, D E Furst has authored 40 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Rheumatology, 14 papers in Pathology and Forensic Medicine and 8 papers in Immunology. Recurrent topics in D E Furst's work include Rheumatoid Arthritis Research and Therapies (18 papers), Systemic Sclerosis and Related Diseases (12 papers) and Systemic Lupus Erythematosus Research (10 papers). D E Furst is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (18 papers), Systemic Sclerosis and Related Diseases (12 papers) and Systemic Lupus Erythematosus Research (10 papers). D E Furst collaborates with scholars based in United States, United Kingdom and Canada. D E Furst's co-authors include P. Emery, Nathalie Lambert, Sean Maloney, Paul C. Evans, J. Lee Nelson, James M. Moore, Marco Matucci‐Cerinic, Deborah Fenlon, George A. Wells and Alan J. Silman and has published in prestigious journals such as Blood, The Journal of Immunology and Radiology.

In The Last Decade

D E Furst

39 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D E Furst United States 22 689 538 470 291 252 40 1.9k
A M Boerbooms Netherlands 24 834 1.2× 462 0.9× 363 0.8× 273 0.9× 44 0.2× 59 1.8k
Sergio Gutiérrez‐Ureña Mexico 17 986 1.4× 144 0.3× 1.2k 2.6× 228 0.8× 363 1.4× 46 2.4k
Akira Sagawa Japan 17 630 0.9× 233 0.4× 539 1.1× 121 0.4× 90 0.4× 75 1.8k
Zora Marjanovic France 22 171 0.2× 907 1.7× 454 1.0× 475 1.6× 61 0.2× 79 2.3k
Aleth Perdriger France 23 857 1.2× 301 0.6× 491 1.0× 371 1.3× 32 0.1× 92 2.0k
Peter Bucsky Germany 21 249 0.4× 531 1.0× 353 0.8× 226 0.8× 113 0.4× 59 2.8k
Zhuoli Zhang China 27 1.1k 1.5× 227 0.4× 563 1.2× 228 0.8× 42 0.2× 141 2.3k
Stanley M. Naguwa United States 26 1.0k 1.5× 273 0.5× 530 1.1× 153 0.5× 24 0.1× 46 2.2k
Gurtej S. Cheema United States 24 1.3k 1.9× 489 0.9× 1.2k 2.5× 283 1.0× 25 0.1× 26 2.9k
Stephen H. Morgan United Kingdom 19 708 1.0× 201 0.4× 153 0.3× 281 1.0× 74 0.3× 42 1.4k

Countries citing papers authored by D E Furst

Since Specialization
Citations

This map shows the geographic impact of D E Furst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D E Furst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D E Furst more than expected).

Fields of papers citing papers by D E Furst

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D E Furst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D E Furst. The network helps show where D E Furst may publish in the future.

Co-authorship network of co-authors of D E Furst

This figure shows the co-authorship network connecting the top 25 collaborators of D E Furst. A scholar is included among the top collaborators of D E Furst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D E Furst. D E Furst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gammill, Hilary S., et al.. (2017). Characterization of the HLA-DRβ1 third hypervariable region amino acid sequence according to charge and parental inheritance in systemic sclerosis. Arthritis Research & Therapy. 19(1). 46–46. 6 indexed citations
2.
Wang, Yukai, Luna Gargani, Tatiana Barskova, D E Furst, & Marco Matucci‐Cerinic. (2017). Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review. Arthritis Research & Therapy. 19(1). 206–206. 106 indexed citations
3.
Huizinga, T., Seán Connolly, Alyssa Johnsen, et al.. (2015). Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate. Data Archiving and Networked Services (DANS). 67. 1 indexed citations
4.
Song, Jae Yeol, et al.. (2015). A cautionary tale: dealing with missing data in clinical trials for rheumatic diseases.. PubMed. 32(6 Suppl 86). S–122. 3 indexed citations
5.
Peterfy, Charles, Gerd R Burmester, V. DiCarlo, et al.. (2014). Sustained Improvements in Magnetic Resonance Imaging Outcomes with Abatacept Following the Withdrawal of All Treatment in Patients with Early Rheumatoid Arthritis. Data Archiving and Networked Services (DANS). 66. 2 indexed citations
6.
Burmester, Gerd R, D E Furst, Bernard Combe, et al.. (2014). Stringent Criteria for Low Disease Activity and Remission after 12 Months of Treatment, and after Treatment Withdrawal, with Abatacept Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis. Data Archiving and Networked Services (DANS). 66. 4 indexed citations
7.
Huizinga, T., Seán Connolly, D E Furst, et al.. (2014). The Impact on Anti-Citrullinated Protein Antibody Isotypes and Epitope Fine Specificity in Patients with Early RA Treated with Abatacept and Methotrexate.. Data Archiving and Networked Services (DANS). 66. 4 indexed citations
8.
Furst, D E, Gerd R Burmester, Bernard Combe, et al.. (2014). Patient-Reported Outcomes Following 12 Months of Therapy with Abatacept (Plus Methotrexate or as Monotherapy) or Methotrexate and up to 6 Months after Treatment Withdrawal in Patients with Early Rheumatoid Arthritis. Data Archiving and Networked Services (DANS). 66. 2 indexed citations
9.
Furst, D E & P. Emery. (2014). Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Lara D. Veeken. 53(9). 1560–1569. 168 indexed citations
10.
Vollenhoven, Ronald van, Paul Emery, Clifton O. Bingham, et al.. (2013). SAT0131 Long-Term Safety of Rituximab: Pooled Analysis of the Rheumatoid Arthritis Global Clinical Trial Programme Over 11 Years. Annals of the Rheumatic Diseases. 72. A625–A626. 2 indexed citations
11.
Bingham, Clifton O., Christoph Pohl, Rieke Alten, et al.. (2009). “Flare” and disease worsening in rheumatoid arthritis: Time for a definition. UWE Research Repository (UWE Bristol). 9 indexed citations
12.
Furst, D E, F C Breedveld, J. R. Kalden, et al.. (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Annals of the Rheumatic Diseases. 66. iii2–iii22. 115 indexed citations
13.
Furst, D E, Norman Gaylis, Ewa Olech, et al.. (2007). Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases. 66(7). 893–899. 88 indexed citations
14.
Furst, D E, et al.. (2006). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Annals of the Rheumatic Diseases. 65. iii2–iii15. 112 indexed citations
15.
Furst, D E, J. Cush, Stefan H. E. Kaufmann, J. Siegel, & R. Kurth. (2002). Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Annals of the Rheumatic Diseases. 61. ii62–ii63. 77 indexed citations
16.
Genovese, Mark C., Shira Cohen, D E Furst, et al.. (2001). Safety Of Combination Therapy With Anakinra And Etanercept In Patients With Rheumatoid Arthritis.. Arthritis & Rheumatism. 44(9). 23 indexed citations
17.
Lambert, Nathalie, Paul C. Evans, Sean Maloney, et al.. (2000). Cutting Edge: Persistent Fetal Microchimerism in T Lymphocytes Is Associated with HLA-DQA1*0501: Implications in Autoimmunity. The Journal of Immunology. 164(11). 5545–5548. 102 indexed citations
18.
Furst, D E, et al.. (1993). Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate.. PubMed. 20(8). 1297–302. 18 indexed citations
19.
Furst, D E. (1988). Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.. PubMed. 17. 58–62. 20 indexed citations
20.
el-Khoury, G Y, Roger K. Larson, Mary H. Kathol, Kevin S. Berbaum, & D E Furst. (1988). Seronegative and seropositive rheumatoid arthritis: radiographic differences.. Radiology. 168(2). 517–520. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026